Med. Pro Praxi 2005; 2: 49-52

Rezistence na aspirin - laboratorní odchylka, nebo klinický problém?

MUDr. Debora Karetová CSc, prof. MUDr. Jan Bultas CSc
II. interní klinika kardiologie a angiologie 1. LF UK a VFN, Praha

Kyselina acetylsalicylová je účinným protidestičkovým lékem, u kterého byl jasně prokázán příznivý vliv na aterotrombotické komplikace u kardiovaskulárních onemocnění. Nicméně se zdá, že jeho účinek není u všech nemocných vyjádřen stejně a možnost „aspirinové rezistence“ by mohla tuto skutečnost, alespoň částečně, vysvětlit. Problémem současnosti je, že pojem rezistence není zcela přesně definován a její prevalence se v různých studiích významně liší (od 5 % do 45 %). V článku jsou diskutovány biologické mechanizmy, laboratorní metody detekce a klinická významnost aspirinové rezistence.

Keywords: Klíčová slova: rezistence k aspirinu, kardiovaskulární choroby, protidestičková léčba.

Published: January 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Karetová D, Bultas J. Rezistence na aspirin - laboratorní odchylka, nebo klinický problém? Med. praxi. 2005;2(2):49-52.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Altman R, Luciardi HL, Muntaner J, et al. The Antithrombotic Profile of Aspirin. Aspirin resistance, or simply failure? Thrombosis Journal 2004, 2: 1. Go to original source... Go to PubMed...
    2. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in high-risk patients. BMJ 2002, 324: 71-86. Go to PubMed...
    3. Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke. Or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002, 105: 1650-1655. Go to original source... Go to PubMed...
    4. Gum PA, Kottke-Marchant K, Poggio ED, et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am. J. Cardiol. 2001; 88: 230-234. Go to original source... Go to PubMed...
    5. Gum PA, Kottke-Marchant K, Welsh PA, et al. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. JACC 2003; 41: 961-965. Go to original source... Go to PubMed...
    6. Hirmerová J, Filipovský J. Klinický význam aspirinové rezistence. Vnitřní lékařství 2004; 50: 462-469. Go to PubMed...
    7. Nicholson NS, Panzer-Knodle SG, Haas NF, et al. Assessment of platelet function assays. Am.Heart J. 1998; 135: S170-S178. Go to original source... Go to PubMed...
    8. Reilly IAG, Fitzgerald GA. Inhibition of thromboxane formation in vivo and ex vivo. Blood 1987; 69: 1366-1372. Go to original source...
    9. Roth GJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. J. Clin. Invest. 1975; 56: 624-632. Go to original source... Go to PubMed...
    10. Sane DC, McKee SA, Malinin AI, Serebruany VL. Frequency of aspirin resistance in patients with congestive heart failure treated with antecedent aspirin. Am. J. Cardiol. 2002; 90: 893-895. Go to original source... Go to PubMed...
    11. Vane JR. Inhibition of prostaglandin syntheses as a mechanism of action for aspirin-like drugs. Nat. New Biol. 1971; 231: 232-325. Go to original source... Go to PubMed...
    12. Vane JR, Bakhle YS, Botting RM. Cyklooxygenases 1 and 2. Ann Rev Pharmacol Toxicol 1998; 38: 97-120. Go to original source... Go to PubMed...
    13. Zimmermann N, Wenk A, Kim U, et al. Functional and Biochemical Evaluation of Platelet Aspirin resistance After Coronary Artery Bypass Surgery. Circulation 2003: 542-547. Go to original source... Go to PubMed...

    Return to the content


    Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.